| |  Online-Ressource |
|---|
| Verfasst von: | Brakemeier, Susanne [VerfasserIn]  |
|---|
| | Arns, Wolfgang [VerfasserIn] |
|---|
| | Lehner, Frank [VerfasserIn] |
|---|
| | Witzke, Oliver [VerfasserIn] |
|---|
| | Vonend, Oliver [VerfasserIn] |
|---|
| | Sommerer, Claudia [VerfasserIn] |
|---|
| | Mühlfeld, Anja [VerfasserIn] |
|---|
| | Rath, Thomas [VerfasserIn] |
|---|
| | Schuhmann, Robert [VerfasserIn] |
|---|
| | Zukunft, Bianca [VerfasserIn] |
|---|
| | Kroeger, Irena [VerfasserIn] |
|---|
| | Porstner, Martina [VerfasserIn] |
|---|
| | Budde, Klemens [VerfasserIn] |
|---|
| Titel: | Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program |
|---|
| Titelzusatz: | results of a prospective randomized multicenter study (SENATOR) |
|---|
| Verf.angabe: | Susanne Brakemeier, Wolfgang Arns, Frank Lehner, Oliver Witzke, Oliver Vonend, Claudia Sommerer, Anja Mühlfeld, Thomas Rath, Robert Schuhmann, Bianca Zukunft, Irena Kroeger, Martina Porstner, Klemens Budde |
|---|
| E-Jahr: | 2019 |
|---|
| Jahr: | September 19, 2019 |
|---|
| Fussnoten: | Gesehen am 14.04.2020 |
|---|
| Titel Quelle: | Enthalten in: PLOS ONE |
|---|
| Ort Quelle: | San Francisco, California, US : PLOS, 2006 |
|---|
| Jahr Quelle: | 2019 |
|---|
| Band/Heft Quelle: | 14(2019,9) Artikel-Nummer e0222730, 17 Seiten |
|---|
| ISSN Quelle: | 1932-6203 |
|---|
| Abstract: | Early conversion to everolimus was assessed in kidney transplant recipients participating in the Eurotransplant Senior Program (ESP), a population in whom data are lacking. The SENATOR multicenter study enrolled 207 kidney transplant recipients undergoing steroid withdrawal at week 2 post-transplant (ClinicalTrials.gov [NCT00956293]). At week 7, patients were randomized (1:2 ratio) to continue the previous calcineurin inhibitor (CNI)-based regimen with mycophenolic acid (MPA) and cyclosporine or switch to a CNI-free regimen with MPA, everolimus (5-10 ng/mL) and basiliximab at weeks 7 and 12, then followed for 18 weeks to month 6 post-transplant. The primary endpoint was estimated GFR (eGFR). At week 7, 77/207 (37.2%) patients were randomized (53 everolimus, 24 control). At month 6, eGFR was comparable: 36.5±10.8ml/min with everolimus versus 42.0±13.0ml/min in the control group (p = 0.784). Discontinuation due to adverse events occurred in 27.8% of everolimus-treated patients and 0.0% of control patients (p = 0005). Efficacy profiles showed no difference. In conclusion, eGFR, safety and efficacy outcomes at month 6 post-transplant showed no difference between groups. The everolimus group experienced a higher rate of discontinuation due to adverse events. However, the high rate of non-randomization is highly relevant, indicating this to be a somewhat unstable patient population regardless of treatment. |
|---|
| DOI: | doi:10.1371/journal.pone.0222730 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1371/journal.pone.0222730 |
|---|
| | Volltext: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222730 |
|---|
| | DOI: https://doi.org/10.1371/journal.pone.0222730 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Adverse events |
|---|
| | Creatinine |
|---|
| | Elderly |
|---|
| | Geriatrics |
|---|
| | Immunosuppressives |
|---|
| | Renal system |
|---|
| | Renal transplantation |
|---|
| | Steroids |
|---|
| K10plus-PPN: | 1694421279 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program / Brakemeier, Susanne [VerfasserIn]; September 19, 2019 (Online-Ressource)
